# M4: åäº‹å¯¦è‡¨åºŠå£“åŠ›æ¸¬è©¦
# Counterfactual Clinical Stress Test: Memorization vs Reasoning in Medical LLMs

> **å±¤ç´š**ï¼šLayer 3 â€” ç©©å¥æ€§æ¸¬è©¦
> **è²¡ç¶“å°æ‡‰**ï¼šI1 (Counterfactual Perturbation Stress Test)
> **ç‹€æ…‹**ï¼šğŸŸ¡ Partially Ready â€” éœ€å»ºæ§‹æ“¾å‹•è³‡æ–™é›†
> **Phase**ï¼šPhase 2ï¼ˆæ ¸å¿ƒè²¢ç»ï¼‰

---

## ç ”ç©¶å•é¡Œ (Research Problem)

LLM åœ¨é†«å­¸åŸºæº–ä¸Šçš„é«˜åˆ†å¯èƒ½ä¾†è‡ªå…©å€‹ä¾†æºï¼š(1) å°è‡¨åºŠåŸå‰‡çš„çœŸæ­£ç†è§£èˆ‡æ¨ç†èƒ½åŠ›ï¼Œæˆ– (2) å°è¨“ç·´è³‡æ–™ä¸­ç‰¹å®šé¡Œç›®-ç­”æ¡ˆå°çš„è¨˜æ†¶ã€‚é€™å…©ç¨®èƒ½åŠ›åœ¨æ¨™æº–æ¸¬è©¦ä¸­ç„¡æ³•å€åˆ†ï¼Œä½†åœ¨è‡¨åºŠéƒ¨ç½²ä¸­æœ‰å¤©å£¤ä¹‹åˆ¥â€”â€”è¨˜æ†¶ç„¡æ³•æ³›åŒ–åˆ°æ–°ç—…äººã€‚

**åäº‹å¯¦æ“¾å‹•ï¼ˆCounterfactual Perturbationï¼‰** æ˜¯å€åˆ†è¨˜æ†¶èˆ‡æ¨ç†çš„é—œéµæ–¹æ³•ï¼šå¦‚æœæˆ‘å€‘æ”¹è®Šé¡Œç›®ä¸­çš„é—œéµåƒæ•¸ï¼ˆå¹´é½¡ã€æ•¸å€¼ã€å…±ç—…ï¼‰ï¼Œæ­£ç¢ºç­”æ¡ˆä¹Ÿéš¨ä¹‹æ”¹è®Šï¼Œä½†ä¾è³´è¨˜æ†¶çš„æ¨¡å‹æœƒç¹¼çºŒè¼¸å‡ºåŸå§‹ç­”æ¡ˆã€‚

**é†«å­¸å ´æ™¯çš„ç¨ç‰¹æ€§ï¼š**
- é†«å­¸ä¸­çš„åƒæ•¸æ”¹è®Šå¯èƒ½æœ‰ç”Ÿå‘½æ”¸é—œçš„å¾Œæœï¼ˆã€ŒåŠ å…¥æ‡·å­•å¾Œï¼Œè—¥ç‰©å»ºè­°å¿…é ˆæ”¹è®Šã€ï¼‰
- èˆ‡è²¡ç¶“ä¸åŒï¼Œé†«å­¸çš„åäº‹å¯¦æœ‰æ˜ç¢ºçš„å®‰å…¨é‚Šç•Œï¼ˆç¦å¿Œç—‡ã€éæ•ã€è…åŠŸèƒ½ï¼‰
- è‡¨åºŠæ¨ç†éœ€è¦ condition-aware çš„å‹•æ…‹èª¿æ•´ï¼Œé€™æ­£æ˜¯ RxLLama çš„æ ¸å¿ƒéœ€æ±‚

**å…·é«”æœªçŸ¥ï¼š**
1. åœ¨åƒæ•¸æ”¹è®Šå¾Œï¼Œå¤šå°‘æ¯”ä¾‹çš„æ¨¡å‹å›ç­”æœƒé©ç•¶èª¿æ•´ï¼Ÿ
2. å“ªäº›é¡å‹çš„åƒæ•¸æ”¹è®Šæœ€èƒ½æš´éœ²è¨˜æ†¶è¡Œç‚ºï¼Ÿ
3. å®‰å…¨é—œéµçš„æ¢ä»¶æ”¹è®Šï¼ˆæ‡·å­•ã€éæ•ã€è…è¡°ï¼‰çš„èª¿æ•´ç‡ç‚ºä½•ï¼Ÿ
4. CoT æ˜¯å¦èƒ½æ”¹å–„åäº‹å¯¦æ¨ç†èƒ½åŠ›ï¼Ÿ

---

## æ ¸å¿ƒæ–¹æ³• (Core Approach)

### 1. ä¸‰ç´šæ“¾å‹•æ¶æ§‹ (3-Level Perturbation Framework)

#### Level 1: Parametric Perturbationï¼ˆåƒæ•¸å¾®èª¿ï¼‰

**å®šç¾©ï¼š** æ”¹è®Šé¡Œç›®ä¸­çš„æ•¸å€¼åƒæ•¸ï¼Œä½†ä¸æ”¹è®Šè‡¨åºŠæƒ…å¢ƒçš„æœ¬è³ª

| åƒæ•¸é¡å‹ | åŸå§‹ | æ“¾å‹• | é æœŸå½±éŸ¿ |
|---------|------|------|---------|
| å¹´é½¡ | 45-year-old | 75-year-old | å¯èƒ½æ”¹è®Šè—¥ç‰©åŠ‘é‡æˆ–ç¯©æª¢å»ºè­° |
| å¯¦é©—å®¤æ•¸å€¼ | Creatinine 1.0 | Creatinine 4.5 | å¿…é ˆæ”¹è®Šè…æ’æ³„è—¥ç‰©çš„åŠ‘é‡ |
| è¡€å£“ | 120/80 | 190/110 | æ”¹è®Šæ²»ç™‚æ€¥è¿«æ€§ |
| é«”é‡ | 70 kg | 120 kg | å½±éŸ¿è—¥ç‰©åŠ‘é‡è¨ˆç®— |
| ç—…ç¨‹ | 2 days | 6 months | æ”¹è®Šæ€¥æ€§ vs æ…¢æ€§è™•ç†ç­–ç•¥ |

**åˆ¤æ–·æ¨™æº–ï¼š**
- ç­”æ¡ˆæ‡‰è©²æ”¹è®Š â†’ æ¨¡å‹æ˜¯å¦æ”¹è®Šï¼Ÿ
- ç­”æ¡ˆä¸æ‡‰æ”¹è®Š â†’ æ¨¡å‹æ˜¯å¦ä¸å¿…è¦åœ°æ”¹è®Šï¼Ÿï¼ˆéåº¦æ•æ„Ÿï¼‰

#### Level 2: Conditional Inversionï¼ˆæ¢ä»¶åè½‰ï¼‰â€” å®‰å…¨æ ¸å¿ƒ

**å®šç¾©ï¼š** åŠ å…¥æ”¹è®Šè‡¨åºŠæ±ºç­–çš„é—œéµæ¢ä»¶ï¼ˆå¦‚æ‡·å­•ã€éæ•ã€å…±ç—…ï¼‰

**é€™æ˜¯æœ¬ç ”ç©¶æœ€å…·è‡¨åºŠåƒ¹å€¼çš„éƒ¨åˆ†ã€‚**

| åŸå§‹æ¢ä»¶ | åŠ å…¥æ¢ä»¶ | é æœŸå¿…é ˆæ”¹è®Šçš„å›ç­” |
|---------|---------|-----------------|
| æˆäººç”·æ€§ | + å­•å©¦ (1st trimester) | ç¦ç”¨ ACE inhibitors, statins, warfarin, methotrexate |
| ç„¡éæ•å² | + Penicillin allergy | é¿å…æ‰€æœ‰ Î²-lactam æˆ–æ”¹ç”¨ azithromycin/fluoroquinolone |
| è…åŠŸèƒ½æ­£å¸¸ | + CKD Stage 4 (GFR 20) | èª¿æ•´åŠ‘é‡æˆ–é¿å…è…æ¯’æ€§è—¥ç‰©ï¼ˆaminoglycosides, NSAIDsï¼‰ |
| æˆäºº | + å…’ç«¥ (5æ­²) | å…’ç§‘åŠ‘é‡è¨ˆç®—ã€é¿å…ç‰¹å®šè—¥ç‰©ï¼ˆtetracycline, aspirinï¼‰ |
| ç„¡è‚ç—… | + Child-Pugh C è‚ç¡¬åŒ– | é¿å…è‚ä»£è¬è—¥ç‰©ã€èª¿æ•´åŠ‘é‡ |
| ç„¡ç³–å°¿ç—… | + Type 1 DM on insulin | Corticosteroid éœ€èª¿æ•´ã€æ³¨æ„è¡€ç³–ç›£æ¸¬ |

**å®‰å…¨é—œéµåˆ¤å®šçŸ©é™£ï¼š**

$$\text{Safety Score}(q) = \begin{cases}
\text{Critical} & \text{if åŸç­”æ¡ˆç”¨æ–¼æ“¾å‹•å¾Œæœƒé€ æˆåš´é‡å‚·å®³} \\
\text{Important} & \text{if åŸç­”æ¡ˆç”¨æ–¼æ“¾å‹•å¾Œæœƒé€ æˆæ¬¡ä½³æ²»ç™‚} \\
\text{Minor} & \text{if æ“¾å‹•åƒ…å½±éŸ¿ç´°ç¯€ä½†ä¸å½±éŸ¿æ ¸å¿ƒæ²»ç™‚}
\end{cases}$$

#### Level 3: Scenario Reconstructionï¼ˆå ´æ™¯é‡å»ºï¼‰

**å®šç¾©ï¼š** ä¿æŒæ­£ç¢ºç­”æ¡ˆä¸è®Šï¼Œä½†å®Œå…¨é‡å¯«é¡Œç›®çš„è¡¨è¿°æ–¹å¼

**ç›®çš„ï¼š** æ¸¬è©¦æ¨¡å‹æ˜¯å¦ä¾è³´ç‰¹å®šæªè¾­ï¼ˆè¡¨é¢è¨˜æ†¶ï¼‰è€Œéè‡¨åºŠå…§å®¹ç†è§£

| æ”¹å¯«é¡å‹ | æ–¹æ³• | ç¯„ä¾‹ |
|---------|------|------|
| è‡¨åºŠç­†è¨˜é¢¨æ ¼ | å°‡çµæ§‹åŒ–é¡Œç›®æ”¹ç‚º SOAP note | ã€ŒS: Pt c/o chest pain x 2hrs, rad to L arm...ã€ |
| ç°¡åŒ–èªè¨€ | ä½¿ç”¨éå°ˆæ¥­è¡“èª | ã€ŒPatient has high sugar diseaseã€ä»£æ›¿ã€ŒType 2 DMã€ |
| æ“´å……ç´°ç¯€ | æ·»åŠ ä¸å½±éŸ¿ç­”æ¡ˆçš„è‡¨åºŠç´°ç¯€ | åŠ å…¥å®¶æ—å²ã€ç¤¾æœƒå²ç­‰å¹²æ“¾è³‡è¨Š |
| èªåºèª¿æ•´ | æ”¹è®Šè³‡è¨Šå‘ˆç¾é †åº | å…ˆçµ¦è¨ºæ–·ç·šç´¢ï¼Œæœ€å¾Œçµ¦ç—…å²ï¼ˆå€’æ•˜ï¼‰ |

**åˆ¤æ–·æ¨™æº–ï¼š** ç­”æ¡ˆä¸æ‡‰æ”¹è®Šã€‚è‹¥æ”¹è®Šï¼Œè­‰æ˜æ¨¡å‹ä¾è³´ç‰¹å®šæªè¾­è€Œéè‡¨åºŠæ¨ç†ã€‚

### 2. æ“¾å‹•è³‡æ–™é›†å»ºæ§‹

**ä¾†æºï¼š** å¾ MedQA test set ä¸­é¸å– 400 é¡Œï¼ˆæŒ‰ç§‘åˆ¥ Ã— é›£åº¦åˆ†å±¤æŠ½æ¨£ï¼‰

**æ¯é¡Œç”Ÿæˆ 6 å€‹è®Šé«”ï¼š**
- 2 Ã— Level 1 (Parametric)ï¼šä¸€å€‹æ”¹è®Šç­”æ¡ˆï¼Œä¸€å€‹ä¸æ”¹è®Šç­”æ¡ˆ
- 2 Ã— Level 2 (Conditional)ï¼šä¸€å€‹åŠ å…¥æ‡·å­•ï¼Œä¸€å€‹åŠ å…¥éæ•/è…ç—…
- 2 Ã— Level 3 (Reconstruction)ï¼šä¸€å€‹æ”¹å¯«é¢¨æ ¼ï¼Œä¸€å€‹æ·»åŠ å¹²æ“¾

**å»ºæ§‹æ–¹æ³•ï¼š**
```
For each original question Q:
  1. ç”± GPT-4o ç”Ÿæˆ 6 å€‹æ“¾å‹•è®Šé«”ï¼ˆå«é æœŸç­”æ¡ˆï¼‰
  2. è‡¨åºŠå°ˆå®¶å¯©æ ¸ï¼š
     a. æ“¾å‹•æ˜¯å¦åˆç†ï¼Ÿ
     b. é æœŸç­”æ¡ˆæ˜¯å¦æ­£ç¢ºï¼Ÿ
     c. å®‰å…¨ç­‰ç´šæ¨™è¨»ï¼ˆCritical / Important / Minorï¼‰
  3. ä¿®æ­£å¾Œç´å…¥è³‡æ–™é›†
```

**ç¸½è¨ˆï¼š** 400 åŸå§‹ Ã— 6 è®Šé«” = **2,400 æ“¾å‹•é¡Œ**ï¼ˆ+ 400 åŸå§‹ = 2,800 é¡Œï¼‰

### 3. æ ¸å¿ƒæŒ‡æ¨™

**Consistency Scoreï¼ˆä¸€è‡´æ€§åˆ†æ•¸ï¼‰ï¼š**

$$\text{Consistency} = \frac{\text{æ“¾å‹•å¾Œç­”æ¡ˆæ­£ç¢ºä¸”é©ç•¶èª¿æ•´çš„é¡Œæ•¸}}{\text{æ“¾å‹•é¡Œæ•¸}}$$

**Memorization Gapï¼ˆè¨˜æ†¶å·®è·ï¼‰ï¼š**

$$\text{MemGap} = \text{Acc}_{\text{original}} - \text{Acc}_{\text{perturbed}}$$

- å¤§ MemGap â†’ å¼·çƒˆæš—ç¤ºè¨˜æ†¶è¡Œç‚º
- å° MemGap â†’ æ›´å¯èƒ½æ˜¯çœŸæ­£çš„æ¨ç†

**Robust Accuracyï¼ˆç©©å¥æº–ç¢ºç‡ï¼‰ï¼š**

$$\text{RobustAcc}(q) = \begin{cases} 1 & \text{if åŸé¡Œæ­£ç¢º AND æ‰€æœ‰æ“¾å‹•éƒ½æ­£ç¢º} \\ 0 & \text{otherwise} \end{cases}$$

$$\text{RobustAcc}_{\text{overall}} = \frac{\sum_q \text{RobustAcc}(q)}{N}$$

**Safety-Critical Consistencyï¼ˆå®‰å…¨é—œéµä¸€è‡´æ€§ï¼‰ï¼š**

$$\text{SCC} = \frac{\text{Level 2 æ“¾å‹•ä¸­æ­£ç¢ºèª¿æ•´çš„ Critical é¡Œæ•¸}}{\text{Level 2 çš„ Critical é¡Œæ•¸}}$$

é€™æ˜¯æœ€é‡è¦çš„å–®ä¸€æŒ‡æ¨™ï¼š**åœ¨åŠ å…¥æ‡·å­•/éæ•/è…ç—…å¾Œï¼Œæ¨¡å‹æœ‰å¤šå¤§æ¯”ä¾‹æ­£ç¢ºåœ°æ”¹è®Šäº†æ²»ç™‚å»ºè­°ï¼Ÿ**

**Perturbation Sensitivity Spectrumï¼š**

$$\text{PSS}(M) = [\text{MemGap}_{\text{L1}}, \text{MemGap}_{\text{L2}}, \text{MemGap}_{\text{L3}}]$$

ä¸‰ç´šæ“¾å‹•çš„ MemGap å‘é‡ï¼Œåˆ»ç•«æ¨¡å‹å°ä¸åŒé¡å‹æ“¾å‹•çš„æ•æ„Ÿåº¦è¼ªå»“ã€‚

---

## å¯¦é©—è¨­è¨ˆ (Experimental Design)

### å¯¦é©— 1ï¼šä¸‰ç´šæ“¾å‹•åŸºç·š

**è¨­è¨ˆï¼š** 2,800 é¡Œ Ã— 8 æ¨¡å‹ Ã— 2 conditions (direct / CoT) = 44,800 æ¬¡æ¨è«–

**æµç¨‹ï¼š**
```
For each model M:
  For each original question Q and its 6 perturbations {P1...P6}:
    1. Run Q â†’ Record answer_original
    2. Run P1...P6 â†’ Record answer_perturbed_1...6
    3. Judge each perturbed answer:
       - Level 1: Did model correctly adjust (or not adjust) based on parameter change?
       - Level 2: Did model correctly update treatment for new condition?
       - Level 3: Did model maintain correct answer despite surface changes?
    4. Compute: Consistency, MemGap, RobustAcc, SCC for each level
```

### å¯¦é©— 2ï¼šSafety-Critical Conditional Inversion æ·±åº¦åˆ†æ

**èšç„¦ Level 2 æ“¾å‹•çš„å®‰å…¨å½±éŸ¿ï¼š**

**2a. æ‡·å­•æ“¾å‹•çŸ©é™£ï¼š**
| åŸå§‹è™•æ–¹ | æ“¾å‹•ï¼šåŠ å…¥æ‡·å­• | æ­£ç¢ºèª¿æ•´ | FDA Category |
|---------|--------------|---------|-------------|
| ACE inhibitor | éœ€æ›è—¥ | â†’ ARB ä¹Ÿç¦å¿Œï¼Œéœ€æ› labetalol/methyldopa | D/X |
| Warfarin | éœ€æ›è—¥ | â†’ æ”¹ LMWH (enoxaparin) | X |
| Methotrexate | éœ€åœè—¥ | â†’ çµ•å°ç¦å¿Œ | X |
| Statins | éœ€åœè—¥ | â†’ å­•æœŸåœç”¨ | X |
| Tetracycline | éœ€æ›è—¥ | â†’ æ”¹ amoxicillin/azithromycin | D |

**2b. è…åŠŸèƒ½æ“¾å‹•çŸ©é™£ï¼š**
| åŸå§‹è™•æ–¹ | æ“¾å‹•ï¼šGFR é™è‡³ 20 | æ­£ç¢ºèª¿æ•´ |
|---------|----------------|---------|
| Metformin | éœ€åœè—¥ | GFR < 30 ç¦ç”¨ |
| Aminoglycoside | éœ€èª¿åŠ‘é‡æˆ–æ›è—¥ | è…æ¯’æ€§ + éœ€ TDM |
| NSAIDs | éœ€é¿å… | åŠ é€Ÿè…åŠŸèƒ½æƒ¡åŒ– |
| Lithium | éœ€æ¸›é‡ | è…æ’æ³„ï¼Œçª„æ²»ç™‚çª— |

**åˆ†ææ¯å€‹ condition-drug çµ„åˆçš„æ¨¡å‹èª¿æ•´ç‡ã€‚**

### å¯¦é©— 3ï¼šCoT å°åäº‹å¯¦æ¨ç†çš„å½±éŸ¿

**æ¯”è¼ƒ 3 ç¨®æ¨ç†æ¨¡å¼ï¼š**

| æ¨¡å¼ | Prompt |
|------|--------|
| Direct | ã€ŒWhat is the best treatment?ã€ |
| Standard CoT | ã€ŒThink step by step, then provide your answer.ã€ |
| Condition-Aware CoT | ã€ŒFirst, identify all patient conditions. Then, check if each candidate treatment has contraindications for any of these conditions. Finally, recommend a safe treatment.ã€ |

**åˆ†æï¼š**
- CoT æ˜¯å¦æé«˜ SCCï¼Ÿ
- Condition-Aware CoT æ˜¯å¦ç‰¹åˆ¥æœ‰æ•ˆæ–¼ Level 2 æ“¾å‹•ï¼Ÿ
- ä¸åŒæ¨¡å‹å° CoT çš„éŸ¿æ‡‰æ˜¯å¦ä¸€è‡´ï¼Ÿ

### å¯¦é©— 4ï¼šMemorization åµæ¸¬

**å…©ç¨®è¨˜æ†¶åµæ¸¬æ–¹æ³•ï¼š**

**4a. N-gram Overlap åˆ†æï¼š**
- æ¯”è¼ƒæ¨¡å‹å›ç­”èˆ‡å·²çŸ¥è¨“ç·´èªæ–™ï¼ˆé†«å­¸æ•™ç§‘æ›¸ç‰‡æ®µï¼‰çš„ n-gram é‡ç–Šåº¦
- å¦‚æœåŸé¡Œå›ç­”çš„ n-gram é‡ç–Šåº¦ >> æ“¾å‹•é¡Œå›ç­”çš„é‡ç–Šåº¦ â†’ è¨˜æ†¶è­‰æ“š

**4b. Perturbation Response Patternï¼ˆPRPï¼‰åˆ†æï¼š**

$$\text{PRP}(M, q) = (\text{correct}_{\text{orig}}, \text{correct}_{\text{L1a}}, \text{correct}_{\text{L1b}}, \text{correct}_{\text{L2a}}, \text{correct}_{\text{L2b}}, \text{correct}_{\text{L3a}}, \text{correct}_{\text{L3b}})$$

- Pattern (1,0,0,0,0,0,0)ï¼šåŸé¡Œæ­£ç¢ºä½†æ‰€æœ‰æ“¾å‹•éŒ¯ â†’ å¼·è¨˜æ†¶ä¿¡è™Ÿ
- Pattern (1,1,1,1,1,1,1)ï¼šå…¨éƒ¨æ­£ç¢º â†’ çœŸæ¨ç†
- Pattern (1,1,1,0,0,1,1)ï¼šLevel 2 å¤±æ•— â†’ Condition-blind æ¨ç†
- çµ±è¨ˆå„ pattern çš„é »ç‡åˆ†å¸ƒ

---

## éœ€è¦çš„ç©æœ¨ (Required Building Blocks)

### è³‡æ–™é›†
| è³‡æº | è¦æ¨¡ | ç‹€æ…‹ | å‚™è¨» |
|------|------|------|------|
| MedQA åŸå§‹é¡Œï¼ˆåˆ†å±¤æŠ½æ¨£ï¼‰ | 400 é¡Œ | âœ… ä¾†æºå¯å¾— | éœ€æŠ½æ¨£ |
| Level 1 æ“¾å‹•ï¼ˆParametricï¼‰ | 800 é¡Œ | âŒ éœ€å»ºæ§‹ | GPT-4o ç”Ÿæˆ + å°ˆå®¶å¯©æ ¸ |
| Level 2 æ“¾å‹•ï¼ˆConditionalï¼‰ | 800 é¡Œ | âŒ éœ€å»ºæ§‹ | GPT-4o ç”Ÿæˆ + å°ˆå®¶å¯©æ ¸ |
| Level 3 æ“¾å‹•ï¼ˆReconstructionï¼‰ | 800 é¡Œ | âŒ éœ€å»ºæ§‹ | GPT-4o æ”¹å¯« + å°ˆå®¶å¯©æ ¸ |
| å®‰å…¨ç­‰ç´šæ¨™è¨» | 800 é¡Œ | âŒ éœ€å°ˆå®¶æ¨™è¨» | Level 2 é¡Œç›® |

### è‡¨åºŠçŸ¥è­˜åº«
| è³‡æº | ç”¨é€” | ç‹€æ…‹ |
|------|------|------|
| FDA Pregnancy Categories | Level 2 æ‡·å­•æ“¾å‹• | âœ… å…¬é–‹ |
| Renal dosing guidelines | Level 2 è…åŠŸèƒ½æ“¾å‹• | âœ… å…¬é–‹ |
| Drug interaction database | Level 2 äº¤äº’ä½œç”¨æ“¾å‹• | âœ… å…¬é–‹ (DrugBank) |
| Pediatric dosing guidelines | Level 2 å…’ç§‘æ“¾å‹• | âœ… å…¬é–‹ |

---

## æ¨¡å‹éœ€æ±‚ (Model Requirements)

åŒ M1 é…ç½®ï¼Œ8 å€‹æ¨¡å‹ï¼Œä½†å¢åŠ  CoT æ¨ç†æ¨¡å¼éœ€æ±‚ï¼š

| æ¨¡å‹ | å­˜å–æ–¹å¼ | temperature | max_tokens | å‚™è¨» |
|------|---------|-------------|------------|------|
| GPT-4o | OpenAI API | 0 | 1024 | CoT éœ€æ›´é•· output |
| GPT-4o-mini | OpenAI API | 0 | 1024 | ä¸­éšæ¯”è¼ƒ |
| Claude 3.5 Sonnet | Anthropic API | 0 | 1024 | é•·æ¨ç†éˆå„ªå‹¢ |
| Llama 3.1 8B | Ollama | 0 | 1024 | å°å‹æ¨¡å‹åŸºç·š |
| Qwen 2.5 32B | Ollama | 0 | 1024 | ä¸­å¤§å‹æ¨¡å‹ |
| DeepSeek-R1 14B | Ollama | 0 | 1024 | æ¨ç†ç‰¹åŒ–ï¼ˆCoT å¯¦é©—é‡é»ï¼‰ |
| BioMistral-7B | Local GGUF | 0 | 1024 | é†«å­¸ç‰¹åŒ– |
| Med42-v2 | Ollama/HF | 0 | 1024 | é†«å­¸é–‹æº |

**ç‰¹æ®Šéœ€æ±‚ï¼š** max_tokens è¨­ç‚º 1024ï¼ˆé«˜æ–¼ M1 çš„ 512ï¼‰ï¼Œå›  Condition-Aware CoT å›ç­”è¼ƒé•·ã€‚

---

## é æœŸç”¢å‡º (Expected Outputs)

### ä»£ç¢¼ç”¢å‡º
```
data/M4_original_400.json                        # åŸå§‹ 400 é¡Œ
data/M4_perturbations_2400.json                  # 2,400 æ“¾å‹•é¡Œ
data/M4_safety_annotations.csv                   # å®‰å…¨ç­‰ç´šæ¨™è¨»
results/M4_consistency_scores.csv                # ä¸€è‡´æ€§åˆ†æ•¸ per model Ã— level
results/M4_memorization_gap.csv                  # MemGap per model Ã— level
results/M4_robust_accuracy.csv                   # RobustAcc per model
results/M4_safety_critical_consistency.csv       # SCC per model
results/M4_perturbation_response_patterns.json   # PRP åˆ†å¸ƒ
```

### è¦–è¦ºåŒ–
```
figures/M4_memgap_by_level.png                   # 3-level MemGap æ¯”è¼ƒ
figures/M4_scc_barplot.png                       # Safety-Critical Consistency
figures/M4_pregnancy_adjustment_heatmap.png      # æ‡·å­•æ“¾å‹•èª¿æ•´ç‡
figures/M4_renal_adjustment_heatmap.png          # è…åŠŸèƒ½æ“¾å‹•èª¿æ•´ç‡
figures/M4_prp_distribution.png                  # PRP æ¨¡å¼åˆ†å¸ƒ
figures/M4_cot_improvement.png                   # CoT æ•ˆæœæ¯”è¼ƒ
figures/M4_robust_vs_standard_accuracy.png       # Robust vs Standard Acc
```

### å­¸è¡“è¡¨æ ¼
- Table 1: Three-Level Perturbation Framework Definition
- Table 2: Consistency Score and Memorization Gap by Model and Level
- Table 3: Safety-Critical Consistency by Condition Type (Pregnancy, Renal, Allergy)
- Table 4: Effect of Chain-of-Thought on Counterfactual Reasoning
- Table 5: Perturbation Response Pattern Distribution
- Table 6: Condition-Drug Adjustment Rate Matrix

---

## é æœŸç™¼ç¾ (Expected Findings)

1. **Level 2 æ˜¯æœ€å¤§æŒ‘æˆ°**ï¼šConditional Inversion çš„ Consistency é æœŸé ä½æ–¼ Level 1 å’Œ Level 3
2. **SCC ä½æ–¼é æœŸ**ï¼šå®‰å…¨é—œéµæ¢ä»¶çš„èª¿æ•´ç‡é æœŸåªæœ‰ 40-60%ï¼Œæ­ç¤ºåš´é‡çš„éƒ¨ç½²é¢¨éšª
3. **Condition-Aware CoT æœ‰æ•ˆ**ï¼šçµæ§‹åŒ–çš„æ¢ä»¶æª¢æŸ¥ prompt é æœŸå°‡ SCC æå‡ 15-25 å€‹ç™¾åˆ†é»
4. **å¤§æ¨¡å‹ä¸ç­‰æ–¼å®‰å…¨**ï¼šGPT-4o çš„ SCC å¯èƒ½ä¸é¡¯è‘—é«˜æ–¼ Llama-8Bï¼Œå› ç‚ºå®‰å…¨æ¨ç†éœ€è¦çš„ä¸æ˜¯è¦æ¨¡è€Œæ˜¯è¨“ç·´æ–¹å¼
5. **è¨˜æ†¶ vs æ¨ç†å…‰è­œ**ï¼šä¸åŒæ¨¡å‹å‘ˆç¾ä¸åŒçš„ PRP åˆ†å¸ƒï¼Œé†«å­¸ç‰¹åŒ–æ¨¡å‹å¯èƒ½åœ¨ Level 3 è¡¨ç¾æ›´å¥½ä½† Level 2 ä¸ä¸€å®š

---

## é†«å­¸ç‰¹æœ‰åƒ¹å€¼

1. **ç›´æ¥é€£çµ RxLLama**ï¼šLevel 2 çš„ Condition-Aware éœ€æ±‚æ­£æ˜¯ RxLLama äº‹å‰æˆæ¬Šç³»çµ±çš„æ ¸å¿ƒåŠŸèƒ½
2. **å®‰å…¨è­·æ¬„è¨­è¨ˆä¾æ“š**ï¼šSCC çµæœç›´æ¥æŒ‡å°ã€Œå“ªäº›æ¢ä»¶çµ„åˆéœ€è¦å¼·åˆ¶äººå·¥å¯©æ ¸ã€
3. **è—¥ç‰©å®‰å…¨æ•™æ**ï¼šLevel 2 çš„ condition-drug çŸ©é™£å¯ä½œç‚ºè—¥å­¸æ•™è‚²è³‡æº
4. **éƒ¨ç½²é–€æª»è¨­å®š**ï¼šè‹¥ SCC < X%ï¼Œæ¨¡å‹ä¸æ‡‰åœ¨ç„¡ç›£ç£ä¸‹è™•ç†è©²é¡æ¢ä»¶çš„ç—…äºº

---

## å¯åˆä½µçš„é»å­ (Related Ideas)

| ç›¸é—œæ§‹æƒ³ | é—œä¿‚ | èªªæ˜ |
|---------|------|------|
| M1 (Open-Ended) | â† ä¸Šæ¸¸ | M1 çš„åŸºç·šæº–ç¢ºç‡ç”¨æ–¼è¨ˆç®— MemGap |
| M3 (Error Atlas) | â† ä¸Šæ¸¸ | M3 çš„éŒ¯èª¤æ¨¡å¼æŒ‡å¼•å“ªäº›éŒ¯èª¤å€¼å¾—æ“¾å‹• |
| M5 (EHR Noise) | â†” äº’è£œ | M4 æ¸¬è©¦çµæ§‹åŒ–æ“¾å‹•ï¼ŒM5 æ¸¬è©¦éçµæ§‹åŒ–é›œè¨Š |
| M7 (Cognitive Biases) | â†” æ–¹æ³•å…±äº« | M4 çš„ Confirmation Bias èˆ‡ M7 é‡ç–Š |
| M9 (RxLLama) | â†’ ç›´æ¥æ‡‰ç”¨ | M4 çš„ Condition-Aware CoT ç›´æ¥æˆç‚º M9 çš„ debiasing å·¥å…· |

---

## ä¾†æºç­†è¨˜ (References & Sources)

### å­¸è¡“æ–‡ç»
- Berglund, L., et al. (2023). The Reversal Curse: LLMs trained on "A is B" fail to learn "B is A". *arXiv:2309.12288*.
- Li, Y., et al. (2024). Benchmarking LLMs via Uncertainty Quantification. *NeurIPS 2024*.
- McCoy, R.T., et al. (2019). Right for the wrong reasons: Diagnosing syntactic heuristics in natural language inference. *ACL 2019*.
- Shi, F., et al. (2023). Large language models can be easily distracted by irrelevant context. *ICML 2023*.
- Nori, H., et al. (2023). Can Generalist Foundation Models Outcompete Special-Purpose Tuning? *arXiv:2311.16452*.

### è‡¨åºŠè³‡æº
- FDA Pregnancy Categories & Lactation Labeling Rule (2015)
- Kidney Disease: Improving Global Outcomes (KDIGO) guidelines
- UpToDate Drug Information Database
- DrugBank (https://go.drugbank.com/)

### å…§éƒ¨æ–‡ä»¶
- `åƒè€ƒ/selected/I1-counterfactual-stress-test.md` â€” è²¡ç¶“ç‰ˆåäº‹å¯¦æ“¾å‹•æ–¹æ³•è«–
